PolyPid Ltd. Ordinary Shares (PYPD) Stock Price
PYPDStock
$4.72+40.90%52W
Market Cap$95.87M
P/E—
PEG Ratio—
Div yield—
Beta1.48
PYPD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-3.12%
Price vs S&P 500 (4W)-7.38%
VGM Score60.97
PYPD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.38 | -$0.35 | +7.28%(+$0.03) | |
| Q1 2026 | -$0.43 | -$0.35 | +19.23%(+$0.08) | |
| Q4 2025 | -$0.33 | -$0.41 | -24.24%(-$0.08) | |
| Q3 2025 | -$0.52 | -$0.37 | +29.19%(+$0.15) | |
| Q2 2025 | -$0.55 | -$0.78 | -42.47%(-$0.23) |
PYPD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.10
4.10
4.10
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
PYPDPolyPid Ltd. Ordinary Shares | — | — | B | — | — | — | — | $4.72 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About PolyPid Ltd. Ordinary Shares
PolyPid Ltd is a clinical-stage biopharmaceutical company developing therapies based on PLEX, its proprietary drug delivery technology that enables targeted, localized drug release over extended periods. The company's lead candidate, D-PLEX100, is being developed to prevent surgical site infections, while OncoPLEX represents a potential intra-tumoral cancer treatment platform.